Direct-from-blood Sepsis Assay
Rapid diagnosis of sepsis and identification of causative pathogens/antibiotic resistance markers
Pre-clinicalActive
Key Facts
Indication
Rapid diagnosis of sepsis and identification of causative pathogens/antibiotic resistance markers
Phase
Pre-clinical
Status
Active
Company
About deepull
deepull is a private, pre-revenue diagnostics company tackling the critical unmet need for rapid sepsis diagnosis. Its core technology is a direct-from-blood multiplex PCR assay targeting approximately 95% of sepsis-causing pathogens, with the goal of providing comprehensive pathogen identification and resistance profiling in roughly one hour, compared to the days required by standard blood cultures. If successfully developed and commercialized, this platform could significantly improve antibiotic stewardship and patient outcomes in sepsis, a condition responsible for millions of deaths globally each year.
View full company profile